Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor
Open Access
- 13 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogenesis
- Vol. 9 (5), 1-13
- https://doi.org/10.1038/s41389-020-0236-x
Abstract
Carbidopa, a peripheral decarboxylase inhibitor used with L-DOPA to treat Parkinson's disease, has attracted significant interest in recent years for its anticancer effect. Increasing evidence reveals that Carbidopa can inhibit cancer cell growth and induce apoptosis through aryl hydrocarbon receptor (AHR) in some cancers. However, the antitumor effect of Carbidopa in prostate cancer (PCa) is not fully understood. Androgen receptor (AR) plays a central role in PCa, even in advanced "castrate-resistant" disease. In the present study, we report that Carbidopa suppresses the growth of PCa by downregulating the protein expression of AR. Carbidopa inhibits proliferation and migration of LNCaP cells and promotes apoptosis, but has no effect on the AR-independent prostate cell line DU145. Carbidopa increases ubiquitination of AR in LNCaP cells. Several studies have shown that AHR can act as an E3 ubiquitin ligase and promote the proteasomal degradation of AR. Quantitative RT-PCR, immunofluorescence staining and immunoblotting assay demonstrate that AHR is induced and activated by Carbidopa, and the co-immunoprecipitation assay shows that AR interacts with AHR, firmly confirming that Carbidopa decreases AR protein level though AHR-induced proteasomal degradation. In addition, Carbidopa suppresses PCa growth in vivo when xenografted into immunocompromised mice. Carbidopa treatment increases AHR protein level and decreases AR protein level in tumor tissues. Taken together, our study implicates Carbidopa for the first time in effective suppression of prostate cancer via a mechanism, involving AHR-mediated proteasomal degradation of AR.Keywords
This publication has 34 references indexed in Scilit:
- Reconsideration of progression to CRPC during androgen deprivation therapyThe Journal of Steroid Biochemistry and Molecular Biology, 2015
- Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug TargetToxicological Sciences, 2013
- Aryl hydrocarbon receptor controls murine mast cell homeostasisBlood, 2013
- DDB2 is a novel AR interacting protein and mediates AR ubiquitination/degradationThe International Journal of Biochemistry & Cell Biology, 2012
- Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's diseaseMovement Disorders, 2012
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion–Resistant GrowthCancer Research, 2009
- Dose translation from animal to human studies revisitedThe FASEB Journal, 2007
- 2,3,7,8-Tetrachlorodibenzo-p-dioxin Blocks Androgen-Dependent Cell Proliferation of LNCaP Cells through Modulation of pRB PhosphorylationMolecular Pharmacology, 2004
- The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells.2000
- Androgen receptor gene and hormonal therapy failure of prostate cancer.1998